利奈唑胺对比万古霉素治疗重症感染的疗效评价

目的评价利奈唑胺与万古霉素在治疗重症感染方面的疗效。方法筛选2020年2—5月入住ICU的确诊或高度怀疑革兰阳性球菌感染患者共19例,随机分为利奈唑胺组及万古霉素组,分别给予常规剂量治疗,比较两组炎症指标、临床疗效及不良反应。结果治疗后,利奈唑胺组相对于万古霉素组在白细胞、降钙素原、C反应蛋白、白介素-6变化的差异无统计学意义,利奈唑胺组临床显效率为55.56%,万古霉素组为60.00%,组间比较差异无统计学意义,两组不良反应发生率比较,差异无统计学意义。结论利奈唑胺对革兰阳性球菌重症感染的疗效与万古霉素无明显差异,临床疗效肯定。

R515 evaluation on the efficacy of linezolid versus vancomycin in the treatment of severe infections

Objective To evaluate the efficacy of linezolid and vancomycin in the treatment of severe infections.Methods A total of 19 patients with confirmed or highly suspected Gram-positive cocci infection who were admitted to the ICU from February 2020 to May 2020 were screened.They were randomly divided into linezolid group and vancomycin group,and were given conventional doses of treatment.The inflammation indicators,clinical efficacy and adverse reactions were compared between the two groups.Results After treatment,there was no statistically significant difference in the changes of leukocytes,procalcitonin,C-reactive protein,and interleukin-6 in the linezolid group compared with the vancomycin group.The clinically significant rate in the linezolid group was 55.56% and that in the vancomycin group was 60.00%.There was no statistically significant difference between the groups.The incidence rate of adverse reactions between the two groups was poor and the difference was not statistically significant.Conclusion The curative effect of linezolid on severe Gram-positive cocci infections is not significantly different from that of vancomycin,and the clinical curative effect is positive.